THE EYENOVIA SOLUTION
All conventional front-of-the-eye therapies are administered using 100-year-old legacy eye-dropper pipette technology, which consistently overdoses the eye with 30-50 μL of toxic preservatives and pharmaceutical ingredients when the eye’s natural, physiologic tear film capacity is only 7-8 μL. An overdose of therapeutics in the eye is often associated with many ocular side effects such as hyperemia, redness, discomfort, foreign body sensation, pigment discoloration, periorbital dermatitis and others. For certain topical medications, there are also major cardiovascular side effects such as bradycardia and arrhythmia that can result from applying too much product to the eye.
High precision micro-dosing can combat these issue by delivering a targeted physiologic dose of 6-8 μL by uniformly coating the corneal surface rather than the conjunctiva in order to reduce collateral tissue exposure and focusing on the cornea where 80% of intraocular drug penetration occurs. Micro-dosing reduces 75-80% of the drug exposure to minimize toxicity leading to an efficient and gentler treatment. In addition, Eyenovia’s smart electronics and mobile e-health technology will transform compliance and chronic disease management by empowering patients and physicians with access to dynamic, real-time monitoring and compliance data for a more intelligent and personalized therapeutic paradigm.
Contact us for more information
Contact us today to learn more about how our microdosing technology is poised to transform the standard of care in ophthalmic therapeutic delivery.
295 Madison Avenue, Suite 2400 NY, NY 10017 [email protected]